<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    9058342
   </pmid>
   <datecreated>
    <year>
     1997
    </year>
    <month>
     05
    </month>
    <day>
     15
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1997
    </year>
    <month>
     05
    </month>
    <day>
     15
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2004
    </year>
    <month>
     11
    </month>
    <day>
     17
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0024-7758
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       42
      </volume>
      <issue>
       2
      </issue>
      <pubdate>
       <year>
        1997
       </year>
       <month>
        Feb
       </month>
      </pubdate>
     </journalissue>
     <title>
      The Journal of reproductive medicine
     </title>
     <isoabbreviation>
      J Reprod Med
     </isoabbreviation>
    </journal>
    <articletitle>
     Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole.
    </articletitle>
    <pagination>
     <medlinepgn>
      83-7
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To evaluate the efficacy of one-day, intermittent, monthly prophylaxis with 400 mg itraconazole in the management of recurrent vulvovaginal candidiasis.
     </abstracttext>
     <abstracttext label="STUDY DESIGN" nlmcategory="METHODS">
      In a randomized trial, 57 patients and 57 controls with recurrent vulvovaginal candidiasis were assigned either to receive one-day monthly itraconazole prophylaxis for six months or no treatment. Clinical and mycologic evaluations were carried out 3, 6 and 12 months after enrollment.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      During the first six months of follow-up, the rate of symptomatic recurrences was 36.4% (20/55) among the treated women and 64.2% (34/53) in the controls. The mean time +/- SEM to symptomatic recurrence was 149 +/- 6 days among patients receiving prophylaxis and 120 +/- 6 days in the controls (P = .003 by log-rank test). These differences disappeared almost completely after the cessation of intermittent prophylaxis. In fact, the proportion of patients still asymptomatic after one year of follow-up was 38.9% (21/54) among treated women and 28.8% (15/53) in the controls (P = .83 by Fisher's exact test).
     </abstracttext>
     <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
      One-day monthly, intermittent itraconazole prophylaxis reduced the rate of recurrence in patients with recurrent vulvovaginal candidiasis, but the beneficial effect of itraconazole was lost within a few months after cessation of prophylaxis.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Obstetrics and Gynecology, University of Pavia, IRCCS Policlinico S. Matteo, Italy.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Spinillo
      </lastname>
      <forename>
       A
      </forename>
      <initials>
       A
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Colonna
      </lastname>
      <forename>
       L
      </forename>
      <initials>
       L
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Piazzi
      </lastname>
      <forename>
       G
      </forename>
      <initials>
       G
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Baltaro
      </lastname>
      <forename>
       F
      </forename>
      <initials>
       F
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Monaco
      </lastname>
      <forename>
       A
      </forename>
      <initials>
       A
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Ferrari
      </lastname>
      <forename>
       A
      </forename>
      <initials>
       A
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     UNITED STATES
    </country>
    <medlineta>
     J Reprod Med
    </medlineta>
    <nlmuniqueid>
     0173343
    </nlmuniqueid>
    <issnlinking>
     0024-7758
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Antifungal Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      84625-61-6
     </registrynumber>
     <nameofsubstance>
      Itraconazole
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Antifungal Agents
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Candidiasis, Vulvovaginal
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug therapy
     </qualifiername>
     <qualifiername majortopicyn="Y">
      prevention &amp; control
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Itraconazole
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Recurrence
     </descriptorname>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1997
     </year>
     <month>
      2
     </month>
     <day>
      1
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      1997
     </year>
     <month>
      2
     </month>
     <day>
      1
     </day>
     <hour>
      0
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1997
     </year>
     <month>
      2
     </month>
     <day>
      1
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     9058342
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

